Clinical trials compared the clinical efficacy in Parkinson's Disease of the more convenient to use extended-release (ER) formulation of the dopamine agonist pramipexole, and the standard immediate-release (IR) pramipexole. Pramipexole is also known as Mirapex, Mirapexin, or Sifrol. For more information go to Mirapex and Mirapex ER. In the first clinical trial, both forms of pramipexole were more effective than a placebo. Both formulations 
(extended release and immediate release) were similarly effective in Parkinson's Disease and were equally tolerated. In the second clinical trial, both forms of pramipexole were more effective than a placebo. Off times decreased by up to 150 minutes per day, but a placebo achieved an 84 minute reduction in off times, thereby lessening the actual reduction in off time to just over an hour per day. Immediate release pramipexole was slightly more effective than extended-release pramipexole, but otherwise, extended-release pramipexole could be readily substituted for immediate-release pramipexole.
(extended release and immediate release) were similarly effective in Parkinson's Disease and were equally tolerated. In the second clinical trial, both forms of pramipexole were more effective than a placebo. Off times decreased by up to 150 minutes per day, but a placebo achieved an 84 minute reduction in off times, thereby lessening the actual reduction in off time to just over an hour per day. Immediate release pramipexole was slightly more effective than extended-release pramipexole, but otherwise, extended-release pramipexole could be readily substituted for immediate-release pramipexole. 
No comments:
Post a Comment